v3.26.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Dec. 17, 2025
Jul. 31, 2024
Jan. 26, 2024
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Mar. 17, 2025
Dec. 31, 2024
Loss Contingencies [Line Items]                
Sales revenue       $ 19,064,000 $ 18,325,000      
Intangible assets, net       5,442,000   $ 5,645,000    
Contingent liability, long-term       0   3,000,000    
Regenity Biosciences                
Loss Contingencies [Line Items]                
Term of agreement   5 years            
Extension term of agreement   5 years            
Payment upon receipt of 510(k) clearance   $ 2,000,000            
Additional payment to guarantee manufacturing capacity $ 3,000,000              
Additional payment term n or before January 4, 2027 on or before January 4, 2026,            
Intangible assets, net               $ 5,000,000
Contingent liability, long-term       3,000,000   3,000,000    
Regenity Biosciences | Maximum                
Loss Contingencies [Line Items]                
Additional payment to guarantee manufacturing capacity   $ 3,000,000            
Threatened Litigation                
Loss Contingencies [Line Items]                
Litigation liability       $ 0   0    
PermeaDerm                
Loss Contingencies [Line Items]                
Sales revenue           $ 6,000,000    
Percentage of increase in revenue from sale       20.00%        
PermeaDerm | Minimum                
Loss Contingencies [Line Items]                
Percentage of share of revenue increased             50.00%  
PermeaDerm | Maximum                
Loss Contingencies [Line Items]                
Percentage of share of revenue increased             60.00%  
PermeaDerm | Stedical Scientific, Inc.                
Loss Contingencies [Line Items]                
Term of agreement     5 years          
Extension term of agreement     5 years